CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sean A. Mccarthy Sells 13,898 Shares

CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sean A. Mccarthy sold 13,898 shares of CytomX Therapeutics stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $1.23, for a total transaction of $17,094.54. Following the completion of the transaction, the chief executive officer now directly owns 657,851 shares in the company, valued at approximately $809,156.73. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

CytomX Therapeutics Stock Down 6.3 %

Shares of CTMX traded down $0.08 during mid-day trading on Thursday, reaching $1.19. The company’s stock had a trading volume of 823,521 shares, compared to its average volume of 3,179,671. CytomX Therapeutics, Inc. has a 1 year low of $1.04 and a 1 year high of $5.85. The company has a market cap of $92.72 million, a price-to-earnings ratio of 6.27 and a beta of 1.06. The business has a fifty day moving average of $1.31 and a 200 day moving average of $1.80.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). CytomX Therapeutics had a net margin of 13.87% and a negative return on equity of 30.70%. The company had revenue of $25.12 million for the quarter, compared to analysts’ expectations of $21.79 million. During the same period in the previous year, the firm posted ($0.02) earnings per share. On average, analysts predict that CytomX Therapeutics, Inc. will post -0.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

CTMX has been the topic of several recent research reports. Jefferies Financial Group upgraded shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and lifted their price target for the stock from $2.50 to $8.00 in a research report on Monday, May 6th. StockNews.com lowered CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, June 17th. Piper Sandler raised CytomX Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $2.25 to $3.50 in a research report on Tuesday, May 28th. HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a research report on Thursday. Finally, BMO Capital Markets lifted their price target on CytomX Therapeutics from $3.25 to $3.59 and gave the stock a “market perform” rating in a research note on Thursday, May 9th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $5.77.

Hedge Funds Weigh In On CytomX Therapeutics

A number of hedge funds have recently modified their holdings of CTMX. SG Americas Securities LLC acquired a new stake in CytomX Therapeutics during the first quarter valued at $57,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of CytomX Therapeutics during the 1st quarter valued at about $124,000. XTX Topco Ltd grew its stake in shares of CytomX Therapeutics by 382.6% in the 2nd quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock valued at $74,000 after buying an additional 48,033 shares in the last quarter. Forefront Analytics LLC increased its holdings in CytomX Therapeutics by 206.7% in the second quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock worth $78,000 after buying an additional 43,176 shares during the last quarter. Finally, Cubist Systematic Strategies LLC increased its holdings in CytomX Therapeutics by 96.6% in the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock worth $100,000 after buying an additional 40,309 shares during the last quarter. 67.77% of the stock is owned by institutional investors and hedge funds.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.